Activating the Value of RWD/RWE in a COVID-19 World

As the industry continues its shift from volume to value, stakeholders are increasingly relying on the power of data, specifically real-world data (RWD), to evaluate drug value. This has made it imperative for manufacturers to consider how best to bring the value of their products to life earlier in the product life cycle. Key industry stakeholders will discuss their plans to expand the innovation horizon and plans to not only leverage technology to support real-world-data collection, but also seek alternative channels and platforms for data capture.